<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Penumbra Inc — News on 6ix</title>
<link>https://6ix.com/company/penumbra-inc</link>
<description>Latest news and press releases for Penumbra Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 13 Apr 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/penumbra-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835ab0c78dffbe2df10d6d0.webp</url>
<title>Penumbra Inc</title>
<link>https://6ix.com/company/penumbra-inc</link>
</image>
<item>
<title>New STORM-PE Data Show Computer Assisted Vacuum Thrombectomy with Anticoagulation Resulted in Significantly Better Functional Outcomes at 90 Days Compared to Anticoagulation Alone for Pulmonary Embolism Patients</title>
<link>https://6ix.com/company/penumbra-inc/news/new-storm-pe-data-show-computer-assisted-vacuum-thrombectomy-with-anticoagulation-resulted-in-significantly-better-functional-outcomes-at-90-days-compared-to-anticoagulation-alone-for-pulmonary-embolism-patients</link>
<guid isPermaLink="true">https://6ix.com/company/penumbra-inc/news/new-storm-pe-data-show-computer-assisted-vacuum-thrombectomy-with-anticoagulation-resulted-in-significantly-better-functional-outcomes-at-90-days-compared-to-anticoagulation-alone-for-pulmonary-embolism-patients</guid>
<pubDate>Mon, 13 Apr 2026 13:00:00 GMT</pubDate>
<description>Penumbra, Inc. (NYSE: PEN) announced 90-day results of the landmark STORM-PE randomized controlled trial (RCT), which found that patients with acute intermediate-high risk pulmonary embolism (PE) who were treated with computer assisted vacuum thrombectomy (CAVT™) plus anticoagulation achieved greater functional improvement, including walking significantly further and a higher proportion of patients achieving NYHA Class I (no physical limitations), compared to anticoagulation alone. The first-of-</description>
</item>
<item>
<title>Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/penumbra-inc/news/penumbra-inc-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/penumbra-inc/news/penumbra-inc-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Wed, 25 Feb 2026 18:00:00 GMT</pubDate>
<description>Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2025.</description>
</item>
<item>
<title>Boston Scientific announces results for fourth quarter and full year 2025</title>
<link>https://6ix.com/company/penumbra-inc/news/boston-scientific-announces-results-for-fourth-quarter-and-full-year-2025</link>
<guid isPermaLink="true">https://6ix.com/company/penumbra-inc/news/boston-scientific-announces-results-for-fourth-quarter-and-full-year-2025</guid>
<pubDate>Wed, 04 Feb 2026 11:30:00 GMT</pubDate>
<description>Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational1 basis and 12.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $672 million or $0.45 per share (EPS), compared to $566 million or $0.38 per share a year ago, and achieved adjusted3 EPS of $0.80 fo</description>
</item>
<item>
<title>Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/penumbra-inc/news/penumbra-inc-provides-preliminary-fourth-120000827</link>
<guid isPermaLink="true">https://6ix.com/company/penumbra-inc/news/penumbra-inc-provides-preliminary-fourth-120000827</guid>
<pubDate>Thu, 15 Jan 2026 12:00:00 GMT</pubDate>
<description>Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced certain unaudited and preliminary financial results for the fourth quarter and full year 2025.</description>
</item>
<item>
<title>Penumbra, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/penumbra-inc/news/penumbra-inc-present-44th-annual-213000489</link>
<guid isPermaLink="true">https://6ix.com/company/penumbra-inc/news/penumbra-inc-present-44th-annual-213000489</guid>
<pubDate>Mon, 29 Dec 2025 21:30:00 GMT</pubDate>
<description>Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026.</description>
</item>
<item>
<title>Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/penumbra-inc/news/penumbra-inc-present-piper-sandler-213000296</link>
<guid isPermaLink="true">https://6ix.com/company/penumbra-inc/news/penumbra-inc-present-piper-sandler-213000296</guid>
<pubDate>Wed, 19 Nov 2025 21:30:00 GMT</pubDate>
<description>Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025.</description>
</item>
<item>
<title>Penumbra, Inc. Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/penumbra-inc/news/penumbra-inc-reports-third-quarter-210500878</link>
<guid isPermaLink="true">https://6ix.com/company/penumbra-inc/news/penumbra-inc-reports-third-quarter-210500878</guid>
<pubDate>Wed, 05 Nov 2025 21:05:00 GMT</pubDate>
<description>Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2025.</description>
</item>
<item>
<title>Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism</title>
<link>https://6ix.com/company/penumbra-inc/news/latest-data-landmark-storm-pe-200000033</link>
<guid isPermaLink="true">https://6ix.com/company/penumbra-inc/news/latest-data-landmark-storm-pe-200000033</guid>
<pubDate>Mon, 03 Nov 2025 20:00:00 GMT</pubDate>
<description>Penumbra, Inc. (NYSE: PEN) announced additional results of the ground-breaking STORM-PE randomized controlled trial (RCT), which found that the use of computer assisted vacuum thrombectomy (CAVT™) with anticoagulation achieved significantly greater improvements in thrombus burden reduction, heart rate, oxygen requirement, and functional outcomes compared to anticoagulation alone in patients with acute intermediate-high risk pulmonary embolism (PE). The data were presented at this week's Vascular</description>
</item>
<item>
<title>Landmark STORM-PE Randomized Controlled Trial Finds Computer Assisted Vacuum Thrombectomy (CAVT) with Anticoagulation Superior to Traditional Anticoagulation Treatment for Pulmonary Embolism</title>
<link>https://6ix.com/company/penumbra-inc/news/landmark-storm-pe-randomized-controlled-130000872</link>
<guid isPermaLink="true">https://6ix.com/company/penumbra-inc/news/landmark-storm-pe-randomized-controlled-130000872</guid>
<pubDate>Mon, 27 Oct 2025 13:00:00 GMT</pubDate>
<description>Penumbra, Inc. (NYSE: PEN) announced the results of the landmark STORM-PE randomized controlled trial (RCT), which found that the use of mechanical thrombectomy, specifically computer assisted vacuum thrombectomy (CAVT™), with anticoagulation achieved superior reduction in right heart strain compared to anticoagulation therapy alone in patients with acute intermediate-high risk pulmonary embolism (PE). The data was presented at a late-breaking session during Transcatheter Cardiovascular Therapeu</description>
</item>
<item>
<title>Penumbra, Inc. Schedules Investor Event at TCT Conference on October 26, 2025; Earnings Release and Conference Call for Third Quarter 2025 Scheduled for November 5, 2025</title>
<link>https://6ix.com/company/penumbra-inc/news/penumbra-inc-schedules-investor-event-203000591</link>
<guid isPermaLink="true">https://6ix.com/company/penumbra-inc/news/penumbra-inc-schedules-investor-event-203000591</guid>
<pubDate>Wed, 08 Oct 2025 20:30:00 GMT</pubDate>
<description>Penumbra, Inc. (NYSE: PEN) today announced that it will host an investor event on Sunday, October 26, 2025 from 4:00-5:00 PM Pacific Time / 7:00-8:00 PM Eastern Time at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) Conference. Management and members of the STORM-PE steering committee will discuss the Company's STORM-PE clinical trial followed by a question-and-answer session. A live webcast of the event can be accessed on the "Events and Presentations" section under the "Investors" ta</description>
</item>
<item>
<title>Penumbra, Inc. Names Shruthi Narayan as Company President</title>
<link>https://6ix.com/company/penumbra-inc/news/penumbra-inc-names-shruthi-narayan-130000485</link>
<guid isPermaLink="true">https://6ix.com/company/penumbra-inc/news/penumbra-inc-names-shruthi-narayan-130000485</guid>
<pubDate>Wed, 27 Aug 2025 13:00:00 GMT</pubDate>
<description>Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today announced the promotion of Shruthi Narayan to President of the company, effective September 1, 2025. She will continue to report to Adam Elsesser, who served in the role of President prior to this promotion and will continue in his roles as chairman of the board and chief executive officer of Penumbra.</description>
</item>
<item>
<title>Penumbra, Inc. to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/penumbra-inc/news/penumbra-inc-present-upcoming-investor-203000715</link>
<guid isPermaLink="true">https://6ix.com/company/penumbra-inc/news/penumbra-inc-present-upcoming-investor-203000715</guid>
<pubDate>Wed, 20 Aug 2025 20:30:00 GMT</pubDate>
<description>Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below.</description>
</item>
<item>
<title>Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference</title>
<link>https://6ix.com/company/penumbra-inc/news/penumbra-inc-present-canaccord-genuity-203000485</link>
<guid isPermaLink="true">https://6ix.com/company/penumbra-inc/news/penumbra-inc-present-canaccord-genuity-203000485</guid>
<pubDate>Wed, 30 Jul 2025 20:30:00 GMT</pubDate>
<description>Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025.</description>
</item>
<item>
<title>Penumbra, Inc. Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/penumbra-inc/news/penumbra-inc-reports-second-quarter-200500465</link>
<guid isPermaLink="true">https://6ix.com/company/penumbra-inc/news/penumbra-inc-reports-second-quarter-200500465</guid>
<pubDate>Tue, 29 Jul 2025 20:05:00 GMT</pubDate>
<description>Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025.</description>
</item>
<item>
<title>Penumbra, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call for July 29, 2025</title>
<link>https://6ix.com/company/penumbra-inc/news/penumbra-inc-schedules-second-quarter-203000715</link>
<guid isPermaLink="true">https://6ix.com/company/penumbra-inc/news/penumbra-inc-schedules-second-quarter-203000715</guid>
<pubDate>Tue, 01 Jul 2025 20:30:00 GMT</pubDate>
<description>Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2025 after market close on Tuesday, July 29, 2025 at 4:30 PM Eastern Time. A press release with second quarter 2025 financial results will be issued after market close that day.</description>
</item>
<item>
<title>Penumbra, Inc. Announces Completion of Enrollment for Landmark STORM-PE Randomized Controlled Trial</title>
<link>https://6ix.com/company/penumbra-inc/news/penumbra-inc-announces-completion-enrollment-130000172</link>
<guid isPermaLink="true">https://6ix.com/company/penumbra-inc/news/penumbra-inc-announces-completion-enrollment-130000172</guid>
<pubDate>Mon, 16 Jun 2025 13:00:00 GMT</pubDate>
<description>Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the completion of enrollment in the STORM-PE clinical trial. The pivotal, prospective, multi-center randomized controlled trial enrolled 100 patients to evaluate computer assisted vacuum thrombectomy (CAVT) using Penumbra's Lightning Flash™ plus anticoagulation, versus anticoagulation alone, for the treatment of acute intermediate-high risk pulmonary embolism (PE).</description>
</item>
<item>
<title>Penumbra Introduces the Ruby® XL System - the Longest, Largest, and Softest Coil on the Market for Vascular Embolization</title>
<link>https://6ix.com/company/penumbra-inc/news/penumbra-introduces-ruby-xl-system-130000774</link>
<guid isPermaLink="true">https://6ix.com/company/penumbra-inc/news/penumbra-introduces-ruby-xl-system-130000774</guid>
<pubDate>Thu, 05 Jun 2025 13:00:00 GMT</pubDate>
<description>Penumbra, Inc. (NYSE: PEN) announced the U.S. Food and Drug Administration (FDA) clearance and launch of the Ruby® XL System, the longest, largest and softest coil on the marketi. The Ruby XL System is designed to help physicians achieve more efficient embolization, potentially reducing radiation exposure, and optimizing outcomes — especially in large vessel and high-flow embolizationii.</description>
</item>
<item>
<title>Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference</title>
<link>https://6ix.com/company/penumbra-inc/news/penumbra-inc-present-bofa-securities-203000191</link>
<guid isPermaLink="true">https://6ix.com/company/penumbra-inc/news/penumbra-inc-present-bofa-securities-203000191</guid>
<pubDate>Tue, 29 Apr 2025 20:30:00 GMT</pubDate>
<description>Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025.</description>
</item>
<item>
<title>Penumbra, Inc. Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/penumbra-inc/news/penumbra-inc-reports-first-quarter-200500535</link>
<guid isPermaLink="true">https://6ix.com/company/penumbra-inc/news/penumbra-inc-reports-first-quarter-200500535</guid>
<pubDate>Wed, 23 Apr 2025 20:05:00 GMT</pubDate>
<description>Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025.</description>
</item>
<item>
<title>Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025</title>
<link>https://6ix.com/company/penumbra-inc/news/penumbra-inc-schedules-first-quarter-203000100</link>
<guid isPermaLink="true">https://6ix.com/company/penumbra-inc/news/penumbra-inc-schedules-first-quarter-203000100</guid>
<pubDate>Thu, 03 Apr 2025 20:30:00 GMT</pubDate>
<description>Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day.</description>
</item>
</channel>
</rss>